ctDNA-guided treatment after esophageal cancer surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial uses a blood test to find tiny bits of tumor DNA after surgery. If the test is positive, you may receive additional therapy to lower the risk of cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older.
- You have a type of esophageal cancer called squamous cell carcinoma.
- You had surgery to remove all visible cancer, with clear margins, between 4 and 16 weeks ago.
- A blood test shows you have minimal residual disease (MRD) after surgery.
- You are in good overall health (able to do daily activities) and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding tislelizumab to chemotherapy or radiation can work better for older adults with advanced or recurrent/metastatic esophageal squamous cell cancer. The goal is to slow the cancer down and improve control of the disease.
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and radiation for older adults (70+) with advanced esophageal cancer that hasn't been treated before. The goal is to see if this approach can help control the cancer while keeping quality of life.
This trial tests whether adding the immunotherapy drug tislelizumab to standard chemotherapy after surgery can help prevent esophageal cancer from coming back. It is for people whose cancer had spread to lymph nodes at the time of surgery.
This trial tests a single immunotherapy drug (tislelizumab) given before surgery for a type of esophageal cancer called squamous cell carcinoma. The goal is to see if it can shrink the tumor and improve outcomes.
This trial tests if adding the immunotherapy drug tislelizumab to standard chemotherapy before surgery or radiation can improve outcomes for people with resectable esophageal squamous cell carcinoma. It is designed for patients whose cancer is in the chest and has not spread to distant organs.
This trial tests whether giving tislelizumab (an immunotherapy) along with chemotherapy before and after surgery can help people with a type of esophageal cancer called squamous cell carcinoma. The goal is to see if this combination improves outcomes for patients whose cancer is in the chest and can be removed with surgery.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.